Active Biotech postpone publication of the interim report
October 26 2016 - 2:25AM
Active Biotech has decided to postpone the
publication of the interim report for January-September 2016 to
November 11, 2016, after stock markets closing. Previously
communicated date was November 10, 2016.
Lund October 26, 2016
For further information, please
contact
Hans Kolam, CFO
Tel. +46 46 19 20 44
Active Biotech AB
(publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties, is in pivotal Phase 3 development for
the treatment of relapsing remitting multiple sclerosis. Also,
laquinimod is in Phase 2 development for the treatment of primary
progressive multiple sclerosis and Huntington's disease.
Furthermore, commercial activities are conducted for the
tasquinimod, SILC, ANYARA and paquinimod projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
161026_new date_Q3
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Sep 2023 to Sep 2024